Oncology and Hematology - Global Oncology Academy

161-176 of 625

Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Project Oncology®
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
Project Oncology®
Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
- Jennifer Caudle, DO, FACOFP
- Andrew Harris, MD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Project Oncology®
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
MinuteCE®
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making  
0.50 credits 4 episodes
- James M. Cleary, MD, PhD
0.50 credits 4 episodes
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 6 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 6 episodes
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
MinuteCE®
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
- Hallie Blevins, PhD
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Global Oncology Academy
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Global Oncology Academy
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- Ryan Quigley

Previous
1
2
…
9
10
11
12
13
…
39
40
Next

11/11